新天药业(002873) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥100,379,992.91, a decrease of 38.09% compared to ¥162,134,733.73 in the same period last year[7] - The net profit attributable to shareholders was ¥3,113,965.50, down 82.04% from ¥17,339,683.60 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥4,182,758.45, representing a 75.21% decrease from ¥16,870,507.43 in the previous year[7] - The basic earnings per share decreased by 81.70% to ¥0.0271 from ¥0.1481 in the same period last year[7] - Total revenue decreased by 38.09% to CNY 100,379,992.91 compared to CNY 162,134,733.73 in the previous period, primarily due to macroeconomic impacts[14] - The company's total equity increased to CNY 730,958,835.01 from CNY 707,444,132.04, an increase of 3.3%[32] - The total operating costs for Q1 2020 were CNY 94,727,324.68, a decrease of 33.7% from CNY 142,728,151.30 in the previous year[41] - The total profit for Q1 2020 was CNY 5,096,667.69, a decrease of 75.6% from CNY 20,864,029.10 in the previous year[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,239,994,713.80, an increase of 14.43% from ¥1,083,647,584.75 at the end of the previous year[7] - Non-current liabilities rose significantly to CNY 184,250,634.05 from CNY 42,193,343.49, marking an increase of 336.5%[31] - Current liabilities decreased to CNY 324,785,244.74 from CNY 332,696,307.79, a reduction of 2.7%[31] - The total liabilities of the company were reported at ¥374,889,651.28, reflecting a stable financial position[52] - The total liabilities and owner's equity combined amounted to CNY 1,062,948,504.63[55] Cash Flow - The net cash flow from operating activities was ¥35,411,350.35, up 17.93% from ¥30,027,733.48 in the same period last year[7] - The cash inflow from operating activities in Q1 2020 was CNY 174,925,614.02, a decrease of 14.3% from CNY 204,307,420.05 in the same period last year[44] - The net cash flow from investing activities was -¥240,316,927.22, compared to -¥30,481,222.23 in Q1 2019, reflecting a significant increase in investment outflows[45] - The net cash flow from financing activities increased dramatically by 1670.82% to CNY 183,676,048.01 from CNY -11,692,968.43, mainly due to funds raised from issuing convertible bonds[14] - The total cash inflow from financing activities was ¥214,800,000.00, significantly higher than ¥28,496,052.72 in the previous year, indicating a substantial increase in financing efforts[46] Shareholder Information - The company reported a total of 18,334 common shareholders at the end of the reporting period[10] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., holds 44.04% of the shares, amounting to 51,568,962 shares[10] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11] - The company repurchased a total of 1,582,500 shares, representing 1.35% of the total share capital, for a total payment of CNY 25,498,647.29[15] - The company plans to use repurchased shares for future employee stock incentive plans[17] Operational Metrics - Accounts receivable decreased by 50.15% to CNY 30,567,171.12 from CNY 61,314,173.32, mainly due to the maturity of bills receivable[14] - The company reported a significant increase in financing receivables, rising by 109.30% to CNY 16,009,256.98 from CNY 7,648,807.97, attributed to increased financing needs[14] - Research and development expenses decreased by 57.92% to CNY 1,942,446.86 from CNY 4,615,701.14, reflecting reduced R&D activities during the period[14] - The company's sales expenses for Q1 2020 were CNY 49,789,784.22, a decrease of 37.3% compared to CNY 79,327,479.52 in the same period last year[41] - The company reported a credit impairment loss of CNY 1,018,351.59 in Q1 2020, indicating potential challenges in asset quality[41] Compliance and Standards - The company has no reported violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[22][23] - The company has not undergone an audit for the first quarter report[56] - The company implemented new revenue and lease standards starting in 2020, with retrospective adjustments not applicable[56]